logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
G

Giuseppe Lamberti

alma mater studiorum-university of bologna
H指数:36
被引数:4,787

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer

DNA甲基转移酶3A（DNMT3A）突变与非小细胞肺癌中PD-(L)1阻断疗法的疗效

Annals of Oncology
IF65.4
2025-06-180
PRE
B. Ricciuti; S. Scalera; X. Wang; A. Elkrief; M. Tagliamento; E. Gariazzo; F. Paoloni; P.G. Miller; F. Pecci; A. Di Federico; V. Santo; J.V. Alessi; M. Aldea; E. Garbo; G. Lamberti; W. Zrafi; J.B. Micol; L.M. Sholl; M. Nishino; F. Cappuzzo; N. Calonaci; G. Caravagna; R. Ferrara; B. Besse; A. Schoenfeld; M. Maugeri-Sacca; M.M. Awad
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study

卡博平、依托泊苷、阿替利珠单抗和贝伐珠单抗在广泛期小细胞肺癌患者的一线治疗中：GOIRC-01-2019 CeLEBrATE 研究

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2025-05-070
OA
Lamberti, Giuseppe; Rihawi, Karim; Mazzoni, Francesca; Riccardi, Ferdinando; Follador, Alessandro; Tiseo, Marcello; Frassoldati, Antonio; Colantonio, Ida; Bonetti, Andrea; Genova, Carlo; Giardina, Donatella; Bertolini, Federica; Cinieri, Saverio; Pasello, Giulia; Brighenti, Matteo; Andrini, Elisa; Tognetto, Michele; Boni, Luca; Ardizzoni, Andrea; GOIRC Grp
Multifocal paraneoplastic encephalitis associated with anti-GABA-B and anti-Hu antibodies manifesting with status epilepticus and epilepsia partialis continua: Expanding the clinical-radiological spectrum

多灶性副肿瘤性脑炎，与抗GABA-B抗体和抗Hu抗体相关，表现为癫痫持续状态和持续性部分性癫痫：扩展临床-影像学谱系

Journal of Neuroimmunology
IF2.5
2025-05-040
PRE
Veronica Viola; Gian Maria Asioli; Lorenzo Ferri; Simone Rossi; Elisa Andrini; Elisabetta Pierucci; Giuseppe Lamberti; Luisa Sambati; Rita Rinaldi; Francesca Bisulli; Luca Spinardi; Maria Guarino
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients

老年非小细胞肺癌患者（≥80岁）的肿瘤免疫表型相关性及PD-L1高表达（≥50%）患者接受一线帕博利珠单抗治疗的结局

Clinical Lung Cancer
IF3.3
2025-02-040
PRE
Adriana P.C. Barrichello; Arielle Elkrief; Biagio Ricciuti; Teja Ganta; Thomas U. Marron; Xinan Wang; William Lotter; James Lindsay; Valentina Santo; Alessio Cortellini; Bijaya Sharma; Kristen Felt; Kathleen Pfaff; Giuseppe Lamberti; Federica Pecci; Alessandro Di Federico; Maisam Makarem; Malini M. Gandhi; Tom Nguyen; Danielle Haradon; Victor R. Vaz; Bruce E. Johnson; Neha Debnath; Yinghong Wang; Andrew G. Kuang; Anwaar Saeed; Maluki Radford; Christine M. Lovly; Caroline A. Nebhan; David J. Pinato; Scott J. Rodig; Adam J. Schoenfeld; Mark M. Awad; Joao V. Alessi; Abdul Rafeh Naqash
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC

STK11、KEAP1和SMARCA4基因拷贝数缺失：临床病理特征及其与免疫治疗联合或单独化疗在非鳞状NSCLC中疗效的关联

Journal of Thoracic Oncology
IF20.8
2025-01-270
PRE
Malini M. Gandhi; Arielle Elkrief; Catherine Gutierrez Moore; Biagio Ricciuti; Joao V. Alessi; Allison L. Richards; Sam Tischfield; Jessica Williams; Giuseppe Lamberti; Federica Pecci; Alessandro Di Federico; Maisam Makarem; Bruce E. Johnson; Mizuki Nishino; Lynette M. Sholl; Adam J. Schoenfeld; Mark M. Awad
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

非小细胞肺癌患者PD-L1表达和肿瘤突变负荷的体内变化及其对免疫检查点抑制剂治疗结局的影响

ANNALS OF ONCOLOGY
IF65.4
2024-10-010
PRE
Di Federico, A.; Alden, S. L.; Smithy, J. W.; Ricciuti, B.; Alessi, J. V.; Wang, X.; Pecci, F.; Lamberti, G.; Gandhi, M. M.; Vaz, V. R.; Spurr, L. F.; Sholl, L. M.; Pfaff, K. L.; Rodig, S. J.; Li, Y. Y.; Cherniack, A. D.; Nishino, M.; Johnson, B. E.; Awad, M. M.
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-09-013
OA
Ricciuti, Biagio; Elkrief, Arielle; Lin, Jessica; Zhang, Jianjun; Alessi, Joao, V; Lamberti, Giuseppe; Gandhi, Malini; Di Federico, Alessandro; Pecci, Federica; Wang, Xinan; Makarem, Maisam; Hidalgo Filho, Cassio Murilo; Gorria, Teresa; Saini, Arushi; Pabon, Cindy; Lindsay, James; Pfaff, Kathleen L.; Welsh, Emma L.; Nishino, Mizuki; Sholl, Lynette M.; Rodig, Scott; Kilickap, Saadettin; Rietschel, Petra; Mcintyre, Debra AG.; Pouliot, Jean-Francois; Altan, Mehmet; Gainor, Justin F.; Heymach, John, V; Schoenfeld, Adam J.; Awad, Mark M.
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
CANCER LETTERS
IF10.1
2024-08-012
OA
Fletcher, Kylie; Cortellini, Alessio; Ganta, Teja; Kankaria, Roma; Song, Haocan; Ye, Fei; Irlmeier, Rebecca; Debnath, Neha; Saeed, Anwaar; Radford, Maluki; Alahmadi, Asrar; Diamond, Akiva; Hoimes, Christopher; Presley, Carolyn J.; Owen, Dwight H.; Abou Alaiwi, Sarah; Nassar, Amin H.; Lamberti, Giuseppe; Perrone, Fabiana; Buti, Sebastiano; Giusti, Raffaele; Filetti, Marco; Vanella, Vito; Mallardo, Domenico; Sussman, Tamara A.; Galetta, Domenico; Kalofonou, Foteini; Daniels, Ella; Ascierto, Paolo A.; Pinato, David J.; Nebhan, Caroline; Berg, Stephanie; Choueiri, Toni K.; Marron, Thomas U.; Wang, Yinghong; Naqash, Abdul Rafeh; Johnson, Douglas B.

研究方向

暂未获取到该数据
D
Davide Campana
H 指数:41论文数:270被引数:5,684
B
Biagio Ricciuti
H 指数:54论文数:1,064被引数:1.0万
M
Mark M. Awad
H 指数:86论文数:1,447被引数:3.0万
E
Elisa Andrini
H 指数:13论文数:59被引数:688
J
Joao V. Alessi
H 指数:28论文数:796被引数:2,968
F
Francesco Panzuto
H 指数:46论文数:311被引数:6,463
A
Alessandro Di Federico
H 指数:30论文数:753被引数:2,982
M
Maria Rinzivillo
H 指数:29论文数:167被引数:2,407
A
Andrea Ardizzoni
H 指数:69论文数:800被引数:2.0万
L
Lynette M. Sholl
H 指数:97论文数:1,164被引数:3.8万